Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration
Publication date: 22 November 2010
Author: Syndicut
Tagged with: Convergence Pharmaceuticals Limited, Ged Giblin, Hans Fliri, Selcia Limited
Convergence Pharmaceuticals Limited (“Convergence”), the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited (“Selcia”), a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain. Under the terms of the agreement, Convergence Pharmaceuticals will apply its ion channel biology platform, medicinal chemistry know-how and preclinical development expertise, recently formed out of GlaxoSmithKline (“GSK”), to Selcia’s medicinal chemistry and chemistry support services. Financial terms were not disclosed.
Commenting on the announcement, Dr Ged Giblin, Head of Chemistry and Preclinical Development at Convergence Pharmaceuticals, said: “Following the successful launch of Convergence Pharmaceuticals with a $35m fund raising, and in-line with our business strategy, this collaboration uniquely enables our goal of identifying novel, high quality, targeted molecules for the treatment of chronic pain. Convergence has a team of highly experienced pain scientists in the field of ion-channel technology and medicinal chemistry and we look forward to maximising the capabilities of Selcia’s expert medicinal and synthetic chemists. We believe the combination of Convergence’s platform and Selcia’s bespoke approach will provide an innovative model for this drug discovery partnership in finding solutions for a major unmet clinical need.”
Selcia’s Managing Director, Dr. Hans Fliri, said: “We are delighted to enter into this partnership with Convergence Pharmaceuticals. At Selcia we are focussed on providing solutions for problems in drug discovery and we have a proven track record of delivering both clinical candidates and added value to our partners’ research programmes. Our customers are able to utilise a flexible, experienced, productive resource and have access to effective proprietary technology. This venture is an exciting development in the area of pain research and we look forward to supporting the Convergence team in reaching their goals.”
In the UK alone, four out of five initial visits to the general practitioner involve pain as the primary symptom, and prescription rates for analgesic medications are the second highest. By 2023 the chronic pain market in the seven major pharmaceutical markets is predicted to reach over $47 billion1. In the same seven pharmaceutical markets, 160 million people are estimated to suffer from osteoarthritis, 36 million people are estimated to suffer from chronic low back pain and sciatica and over 10 million people are estimated to suffer from neuropathic pain.
Reference
- Source: Decision Resources Inc, Novel Approaches to Pain Therapy August 2008
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Daiichi Sankyo and the National Cancer Center form comprehensive research alliance (22 May 2012)
- Fast plasma sample cleanup with new Phree Phospholipid Removal Plates (21 May 2012)
- FDA approves new labeling for ISENTRESS® (raltegravir) (21 May 2012)
- Capital increase in Lundbeck as a result of employee warrant programme (21 May 2012)
- Two overall winners announced at prestigious national award ceremony in London’s Science Museum (18 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content